Clinical Trial Update: Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating alemtuzumab for Chronic Inflammatory Demyelinating Polyneuropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Chronic Inflammatory Demyelinating Neuropathy | Phase 4 | Status: WITHDRAWN